Thomas John Dietz Paratek Pharmaceuticals, Inc. (PRTK) insider trading activity

Thomas John Dietz is Director of Paratek Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of PRTK, which is worth approximately $0. The most recent transaction as insider was on Sep 21, 2023, when has been sold 69,250 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

Thomas John Dietz Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 21 2023	SELL Sale (or disposition) back to the issuer	-	69,250 Reduced 100.0%	0 Common Stock
Feb 08 2023	BUY Grant, award, or other acquisition	-	20,000 Added 22.22%	70,000 Common Stock
Feb 16 2022	BUY Grant, award, or other acquisition	-	20,000 Added 28.57%	50,000 Common Stock
Feb 18 2021	BUY Grant, award, or other acquisition	-	9,000 Added 23.08%	30,000 Common Stock

Also insider at

LPTX

LEAP THERAPEUTICS, INC. Healthcare

Director

EIGR

Eiger BioPharmaceuticals, Inc. Healthcare

TJD